Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
EClinicalMedicine. 2023 Sep 21;64:102240. doi: 10.1016/j.eclinm.2023.102240. eCollection 2023 Oct.
EClinicalMedicine. 2023.
PMID: 37767191
Free PMC article.
INTERPRETATION: Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with advanced STS. FUNDING: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., the National Key Research and Development Program of China, an …
INTERPRETATION: Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with ad …
Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C, Zhu L, Jia X, Pang Y, Li Z, Lu X, Xie F, Duan L, Wang Y.
Zeng C, et al.
Gastric Cancer. 2020 Sep;23(5):837-847. doi: 10.1007/s10120-020-01069-1. Epub 2020 Apr 6.
Gastric Cancer. 2020.
PMID: 32291709
Item in Clipboard
Cite
Cite